---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-326784"
form_type: "8-K"
ticker: "TENX"
cik: "0000034956"
company_name: "TENAX THERAPEUTICS, INC."
filed_at: "2026-07-31T11:23:10+00:00"
generated_at: "2026-07-31T11:25:13.177922+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Tenax Therapeutics Q2 net loss $17.8M; cash $118M; Phase 3 LEVEL topline data expected Aug 2026

## Summary
- Net loss of $17.8M for Q2 2026, compared to $10.9M in Q2 2025.
- Cash and cash equivalents of $118.0M as of June 30, 2026; cash runway extended through Q2 2028.
- R&D expenses rose to $12.9M from $6.1M, driven by Phase 3 LEVEL and LEVEL-2 trials.
- Proceeds of $13.4M from warrant exercises in Q2 2026.
- Topline data from Phase 3 LEVEL trial expected in August 2026; LEVEL-2 enrollment targeted by end of 2027.

## SEC filing metadata
- accession: 0001193125-26-326784
- form_type: 8-K
- ticker: TENX
- cik: 0000034956
- company_name: TENAX THERAPEUTICS, INC.
- filed_at: 2026-07-31T11:23:10+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/34956/000119312526326784/0001193125-26-326784-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/34956/000119312526326784/d90330d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-326784
- JSON: https://secwatch.observer/filing/0001193125-26-326784.json
- Plain text: https://secwatch.observer/filing/0001193125-26-326784.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.